<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339910</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0901</org_study_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>U01HL069294-05</secondary_id>
    <secondary_id>BMT CTN 0901</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT01339910</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)</brief_title>
  <official_title>A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic
      hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or
      myelodysplastic syndrome (MDS) between patients receiving myeloablative conditioning (MAC)
      versus reduced intensity conditioning (RIC) regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients randomized to RIC will receive one of two regimen types: the combination of
      fludarabine (120-180 mg/m^2) and busulfan (less than or equal to 8 mg/kg or IV equivalent)
      (Flu/Bu) or fludarabine (120-180 mg/m^2) and melphalan (less than 150 mg/m^2) (Flu/Mel).
      Patient randomized to MAC will receive one of three regimens: busulfan (16 mg/kg oral or 12.8
      mg/kg IV equivalent) and cyclophosphamide (120 mg/kg) (Bu/Cy); or, busulfan (16 mg/kg PO or
      12.8 mg/kg IV) and fludarabine (120-180 mg/m^2) (Bu/Flu); or, cyclophosphamide (120 mg/kg)
      and total body irradiation (greater than 1200-1420cGy) (CyTBI). A total of 356 patients (178
      to each arm) will be accrued on this study over a period of four years. Patients will be
      followed for up to 18 months from transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual terminated as recommended by the data and safety monitoring board.
  </why_stopped>
  <start_date type="Actual">June 2011</start_date>
  <completion_date type="Actual">October 16, 2017</completion_date>
  <primary_completion_date type="Actual">January 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS)</measure>
    <time_frame>18 months post-randomization</time_frame>
    <description>Overall survival is defined as survival of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Relapse-Free Survival (RFS)</measure>
    <time_frame>18 months post-randomization</time_frame>
    <description>Relapse-free survival is defined as survival without relapse of the primary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Relapse</measure>
    <time_frame>18 months post-randomization</time_frame>
    <description>Disease Relapse is defined as relapse of the primary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-related Mortality</measure>
    <time_frame>18 months post-randomization</time_frame>
    <description>Treatment-related mortality is defined as death without a previous relapse of the primary disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Neutrophil and Platelet Engraftment</measure>
    <time_frame>Days 28 and 60 post-transplant</time_frame>
    <description>Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Donor Cell Engraftment</measure>
    <time_frame>Days 28 and 100 and 18 months post-transplant</time_frame>
    <description>Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>Day 100 post-transplant</time_frame>
    <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chronic GVHD</measure>
    <time_frame>18 months post-transplant</time_frame>
    <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic GVHD Severity</measure>
    <time_frame>18 months post-transplant</time_frame>
    <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Primary Graft Failure</measure>
    <time_frame>28 days post-transplant</time_frame>
    <description>Primary graft failure is defined by lack of neutrophil engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Secondary Graft Failure</measure>
    <time_frame>18 months post-transplant</time_frame>
    <description>Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maximum Grade 3-5 Toxicities</measure>
    <time_frame>18 months</time_frame>
    <description>The maximum grade of toxicities reported by participants over the study duration are tabulated. Per the CTCAE criteria, toxicities are graded on a scale of 0-5, with higher numbers indicating greater severity. The categories correspond as follows:
3 - severe; 4 - life-threatening; 5 - fatal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection Type</measure>
    <time_frame>18 months post-transplant</time_frame>
    <description>The number and types of infection events reported are tabulated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infections</measure>
    <time_frame>18 months post-transplant</time_frame>
    <description>The maximum severity of infections reported by participants are tabulated.
The number of infections and the number of patients experiencing infections will be tabulated by type of infection, severity, and time period after transplant. The cumulative incidence of severe, life-threatening, or fatal infections will be compared between the two treatment arms at 6, 12, and 18 months from transplant or until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cause of Death</measure>
    <time_frame>18 months post-randomization</time_frame>
    <description>Primary cause of death was adjudicated using previously described criteria (Copelan et al. 2007). When relapse occurred, it was considered the primary cause of death regardless of other events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <arm_group>
    <arm_group_label>Reduced Intensity Conditioning (RIC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloablative Conditioning Regimen (MAC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine and Busulfan</intervention_name>
    <description>(Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4</description>
    <arm_group_label>Reduced Intensity Conditioning (RIC)</arm_group_label>
    <other_name>Fludara and Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine and Melphalan</intervention_name>
    <description>(Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
    <arm_group_label>Reduced Intensity Conditioning (RIC)</arm_group_label>
    <other_name>Fludara and Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan and Fludarabine</intervention_name>
    <description>(Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)</description>
    <arm_group_label>Myeloablative Conditioning Regimen (MAC)</arm_group_label>
    <other_name>Busulfex and Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan and Cyclophosphamide</intervention_name>
    <description>(Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
    <arm_group_label>Myeloablative Conditioning Regimen (MAC)</arm_group_label>
    <other_name>Busulfex and Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide and Total Body Irradiation</intervention_name>
    <description>(Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
    <arm_group_label>Myeloablative Conditioning Regimen (MAC)</arm_group_label>
    <other_name>Cytoxan and radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or less than 65 years old and equal to or greater than 18 years old.

          -  Patients with the diagnosis of MDS or AML with fewer than 5% myeloblasts in the bone
             marrow and no leukemic myeloblasts in the peripheral blood on morphologic analysis
             performed within 30 days of start of the conditioning regimen enrollment.

          -  For patients receiving treatment of their MDS or AML prior to transplantation:
             a)Interval between the start of the most recent cycle of conventional cytotoxic
             chemotherapy and enrollment must be at least 30 days; b)Interval between completing
             treatment with a hypomethylating agent or other non-cytotoxic chemotherapy and
             enrollment must be at least 10 days.

          -  Patients must have a related or unrelated bone marrow or peripheral blood donor who is
             human leukocyte antigen (HLA)-matched at 7 or 8 of 8 HLA-A, -B, -C and -DRB1 at high
             resolution using DNA-based typing.

          -  HCT-Specific Comorbidity Index Score (HCT-CI) less than or equal to 4.

          -  Organ function: a) Cardiac function: Ejection fraction greater than or equal to 40%;
             b) Hepatic function: total bilirubin less than or equal to 2 times the upper limit of
             normal and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less
             than or equal to 3 times the upper limit of normal.; c)Pulmonary function: Diffusing
             capacity of the lung for carbon monoxide (DLCO) greater than or equal to 40% and
             forced expiratory volume in one second (FEV1) greater than or equal to 50% (corrected
             for hemoglobin).

          -  Creatinine clearance greater than or equal to 50mL/min based on the Cockcroft-Gault
             formula.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Prior allograft or prior autograft.

          -  Symptomatic coronary artery disease.

          -  Leukemia involvement in the central nervous system (CNS) within 4 weeks of enrollment
             for patients with a history of prior CNS leukemia involvement (i.e., leukemic blasts
             previously detected in the cerebral spinal fluid).

          -  Karnofsky Performance Score less than 70.

          -  Patients receiving supplemental oxygen.

          -  Planned use of donor lymphocyte infusion (DLI) therapy.

          -  Patients with uncontrolled bacterial, viral or fungal infections (undergoing
             appropriate treatment and with progression of clinical symptoms).

          -  Patients seropositive for the human immunodeficiency virus (HIV).

          -  Patients with prior malignancies, except resected basal cell carcinoma or treated
             cervical carcinoma in situ. Cancer treated with curative intent greater than 5 years
             previously. Cancer treated with curative intent less than 5 years previously will not
             be allowed unless approved by the Protocol Officer or one of the Protocol Chairs.

          -  Females who are pregnant or breastfeeding.

          -  Fertile men and women unwilling to use contraceptive techniques during and for 12
             months following treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Program at Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI, Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital BMT Program</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah BMT/University of Utah Medical School</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <reference>
    <citation>Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8. Review.</citation>
    <PMID>19357394</PMID>
  </reference>
  <reference>
    <citation>Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9. Epub 2005 Jun 30.</citation>
    <PMID>15994282</PMID>
  </reference>
  <reference>
    <citation>Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.</citation>
    <PMID>16338616</PMID>
  </reference>
  <reference>
    <citation>Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007 Dec;13(12):1469-76.</citation>
    <PMID>18022577</PMID>
  </reference>
  <results_reference>
    <citation>Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.</citation>
    <PMID>28380315</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <results_first_submitted>March 12, 2018</results_first_submitted>
  <results_first_submitted_qc>May 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2018</results_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings will be published in a manuscript</ipd_description>
    <ipd_time_frame>Within 6 months of official study closure at participating sites.</ipd_time_frame>
    <ipd_access_criteria>Available to the public.</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between June 2011 and April 2014 from 32 transplant centers</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Myeloablative Conditioning Regimen (MAC)</title>
          <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
        </group>
        <group group_id="P2">
          <title>Reduced Intensity Conditioning (RIC)</title>
          <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease relapse</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Myeloablative Conditioning Regimen (MAC)</title>
          <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
        </group>
        <group group_id="B2">
          <title>Reduced Intensity Conditioning (RIC)</title>
          <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" lower_limit="21.9" upper_limit="66.0"/>
                    <measurement group_id="B2" value="54.8" lower_limit="21.9" upper_limit="65.9"/>
                    <measurement group_id="B3" value="54.8" lower_limit="21.9" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Acute Myeloid Leukemia (AML)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myelodysplastic Syndrome (MDS)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS WHO Classification</title>
          <description>Participants with MDS are categorized per 2008 WHO classification (Vardiman et al. 2009). Major features of each class are given below:
Refractory Anemia (RA): Anemia without marrow blasts or sideroblasts; Refractory Anemia with Ringed Sideroblasts (RARS): &gt; 15% marrow sideroblasts; Refractory Cytopenias with Multilineage Dysplasia (RCMD): Dysplasia in &gt;10% marrow cells; Isolated del(5q) (Del-5q): Isolated del(5q) in marrow; Unclassified (MDS-U) Refractory Anemia with Excess Blasts-1 (RAEB-1): 5-9% marrow blasts; Refractory Anemia with Excess Blasts-2 (RAEB-2): 10-19% marrow blasts;</description>
          <population>Participants with MDS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>RA/RARS/RCMD/RCMD-RS/Del-5q/MDS-U</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>RAEB-1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>RAEB-2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AML WHO Classification</title>
          <description>Participants with AML are categorized per 2008 WHO classification (Vardiman et al. 2009). Major features of each class are given below:
AML with recurrent genetic abnormalities: Presence of specific genetic abnormalities known to be prognostic; AML with multilineage dysplasia: &gt; 50% of cells in at least 2 myeloid lineages are dysplastic; AML and MDS, therapy related: development of myeloid neoplasms in response to therapy that is diagnosed as either AML or MDS; AML not otherwise specified: AML that does not satisfy criteria for other classes</description>
          <population>Participants with AML</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>AML with recurrent genetic abnormalities</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AML with multilineage dysplasia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AML and MDS, therapy related</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AML, not otherwise specified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Duration</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="2" upper_limit="86"/>
                    <measurement group_id="B2" value="6" lower_limit="2" upper_limit="130"/>
                    <measurement group_id="B3" value="6" lower_limit="2" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Risk Status</title>
          <description>Disease risk status is defined according to cytogenetic and molecular abnormalities identified prior to transplantation and classified as standard or high risk. Among AML participants, high-risk disease is defined as the presence of cytogenetic abnormalities at 3q, 9q, 11q, 20q, 21q, or 17p; the presence of del(5q)/-5, -7/del(7q), t(6;9), or t(9;22); and/or FLT-3 internal tandem duplication mutation. Among MDS participants, high-risk disease is defined as the presence of &gt; 10% blasts in bone marrow.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Standard</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCT-CI</title>
          <description>The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) (Sorror et al., 2005) summarizes relevant comorbidities present in participants prior to allogeneic transplant. Each comorbidity reported at the time of transplant is given a score of 0, 1, 2, or 3 and the overall HCT-CI score is the sum of the comorbidity scores, ranging from 0 - 26.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 or more</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conditioning Regimen</title>
          <description>Flu/Bu4: busulfan (16 mg/kg oral or 12.8 mg/kg IV) and fludarabine (120-180 mg/m2); Bu/Cy: busulfan (16 mg/kg oral or 12.8 mg/kg IV) and cyclophosphamide (120 mg/kg) ; Cy/TBI: cyclophosphamide (120 mg/kg) and total body irradiation (1200-1420 cGy); Flu/Mel: fludarabine (120-180 mg/m2) and melphalan (≤ 150 mg/m2); Flu/Bu2: fludarabine (120-180 mg/m2) with busulfan (≤ 8 mg/kg oral or 6.4 mg/kg IV);
Flu/Bu4, Bu/Cy, and Cy/TBI are myeloablative conditioning regimens, while Flu/Mel and Flu/Bu2 are reduced intensity conditioning regimens.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Flu/Bu4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bu/Cy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cy/TBI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Flu/Mel</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Flu/Bu2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GVHD Prophylaxis</title>
          <description>Prophylaxis for Graft Versus Host Disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Tacrolimus / Methotrexate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cyclosporine / Methotrexate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>TAC / Mycophenolate mofetil</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cyclosporine / Mycophenolate mofetil</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sirolimus / Tacrolimus</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ATG Use</title>
          <description>Use of Anti-Thymocyte Globulin</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Matched Related</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mismatched Related</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Matched Unrelated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mismatched Unrelated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Source</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="135"/>
                    <count group_id="B2" value="137"/>
                    <count group_id="B3" value="272"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Peripheral Blood</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bone Marrow</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Overall Survival (OS)</title>
        <description>Overall survival is defined as survival of death from any cause.</description>
        <time_frame>18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS)</title>
          <description>Overall survival is defined as survival of death from any cause.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="69.4" upper_limit="83.7"/>
                    <measurement group_id="O2" value="67.7" lower_limit="59.1" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in overall survival at 18 months post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. 18 month overall survival was compared between treatment arms using the difference in Kaplan-Meier estimators, which should be close to 0 under the null hypothesis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>This final test was performed at a 0.049 significance level, since 0.001 was spent at interim analyses and the overall significance level was 0.050.</p_value_desc>
            <method>Difference in Kaplan-Meier estimators</method>
            <param_type>Difference in 18 month OS (MAC-RIC)</param_type>
            <param_value>9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>20.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Relapse-Free Survival (RFS)</title>
        <description>Relapse-free survival is defined as survival without relapse of the primary disease.</description>
        <time_frame>18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Relapse-Free Survival (RFS)</title>
          <description>Relapse-free survival is defined as survival without relapse of the primary disease.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" lower_limit="59.1" upper_limit="75.0"/>
                    <measurement group_id="O2" value="47.3" lower_limit="38.7" upper_limit="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in relapse-free survival at 18 months post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. 18 month relapse-free survival was compared between treatment arms using the difference in Kaplan-Meier estimators, which should be close to 0 under the null hypothesis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.01</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Difference in Kaplan-Meier estimators</method>
            <param_type>Difference in 18 month RFS (MAC-RIC)</param_type>
            <param_value>20.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>32.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Relapse</title>
        <description>Disease Relapse is defined as relapse of the primary disease.</description>
        <time_frame>18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Relapse</title>
          <description>Disease Relapse is defined as relapse of the primary disease.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="8.3" upper_limit="19.8"/>
                    <measurement group_id="O2" value="48.3" lower_limit="39.6" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of disease relapse during the first 18 months post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of disease relapse was compared between treatment arms using Gray's test, treating death as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Gray's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-related Mortality</title>
        <description>Treatment-related mortality is defined as death without a previous relapse of the primary disease.</description>
        <time_frame>18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-related Mortality</title>
          <description>Treatment-related mortality is defined as death without a previous relapse of the primary disease.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="10.2" upper_limit="22.5"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.8" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of treatment-related mortality during the first 18 months post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of treatment-related mortality was compared between treatment arms using Gray's test, treating disease relapse as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Gray's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Neutrophil and Platelet Engraftment</title>
        <description>Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days.</description>
        <time_frame>Days 28 and 60 post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Neutrophil and Platelet Engraftment</title>
          <description>Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days.</description>
          <population>Transplanted participants</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Engraftment at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment at Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                    <measurement group_id="O2" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of neutrophil engraftment at Day 28 post-transplant between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of neutrophil engraftment at Day 28 was compared between treatment arms using the difference in Aalen-Johansen estimators, which should be close to 0 under the null hypothesis. Death was treated as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Difference in Aalen-Johansen estimators</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of platelet engraftment at Day 60 post-transplant between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of platelet engraftment at Day 60 was compared between treatment arms using the difference in Aalen-Johansen estimators, which should be close to 0 under the null hypothesis. Death was treated as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Difference in Aalen-Johansen estimators</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Donor Cell Engraftment</title>
        <description>Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment.</description>
        <time_frame>Days 28 and 100 and 18 months post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Donor Cell Engraftment</title>
          <description>Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment.</description>
          <population>Transplanted participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <title>Full Donor Chimerism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Chimerism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Graft Rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death Prior to Assessment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown (relapsed or missing assay)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <title>Full Donor Chimerism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Chimerism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Graft Rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death Prior to Assessment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown (relapsed or missing assay)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months</title>
              <category_list>
                <category>
                  <title>Full Donor Chimerism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Chimerism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Graft Rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death Prior to Assessment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown (relapsed or missing assay)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the proportions of participants with full chimerism, mixed chimerism, graft rejection, and death prior to assessment at Day 28 post-transplant between AML/MDS participants receiving MAC and RIC conditioning regimens.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>3 degrees of freedom</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the proportions of participants with full chimerism, mixed chimerism, graft rejection, and death prior to assessment at Day 100 post-transplant between AML/MDS participants receiving MAC and RIC conditioning regimens.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>3 degrees of freedom</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the proportions of participants with full chimerism, mixed chimerism, graft rejection, and death prior to assessment at 18 months post-transplant between AML/MDS participants receiving MAC and RIC conditioning regimens.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>3 degrees of freedom</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Acute Graft Versus Host Disease (GVHD)</title>
        <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
        <time_frame>Day 100 post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Acute Graft Versus Host Disease (GVHD)</title>
          <description>Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:
Skin stage:
0: No rash
Rash &lt;25% of body surface area
Rash on 25-50% of body surface area
Rash on &gt; 50% of body surface area
Generalized erythroderma with bullous formation
Liver stage (based on bilirubin level)*:
0: &lt;2 mg/dL
2-3 mg/dL
3.01-6 mg/dL
6.01-15.0 mg/dL
&gt;15 mg/dL
GI stage*:
0: No diarrhea or diarrhea &lt;500 mL/day
Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD
Diarrhea 1000-1499 mL/day
Diarrhea &gt;1500 mL/day
Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.
GVHD grade:
0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4</description>
          <population>Transplanted participants</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="36.0" upper_limit="53.0"/>
                    <measurement group_id="O2" value="31.6" lower_limit="23.8" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="8.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="6.8" lower_limit="3.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of grade II-IV acute GVHD during the first 100 days post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of grade II-IV acute GVHD was compared between treatment arms using Gray's test, treating death as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Gray's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of grade III-IV acute GVHD during the first 100 days post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of grade III-IV acute GVHD was compared between treatment arms using Gray's test, treating death as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.066</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Gray's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chronic GVHD</title>
        <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.</description>
        <time_frame>18 months post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chronic GVHD</title>
          <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification.</description>
          <population>Transplanted participants</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="55.0" upper_limit="71.7"/>
                    <measurement group_id="O2" value="47.6" lower_limit="38.8" upper_limit="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the cumulative incidence of chronic GVHD during the first 18 months post-randomization between AML/MDS participants receiving MAC and RIC conditioning regimens. Cumulative incidence of chronic GVHD was compared between treatment arms using Gray's test, treating death as a competing risk.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>Test performed at a significance level of 0.05</p_value_desc>
            <method>Gray's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic GVHD Severity</title>
        <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe.</description>
        <time_frame>18 months post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic GVHD Severity</title>
          <description>Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe.</description>
          <population>Transplanted participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Primary Graft Failure</title>
        <description>Primary graft failure is defined by lack of neutrophil engraftment.</description>
        <time_frame>28 days post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Graft Failure</title>
          <description>Primary graft failure is defined by lack of neutrophil engraftment.</description>
          <population>Transplanted participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Secondary Graft Failure</title>
        <description>Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy.</description>
        <time_frame>18 months post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Secondary Graft Failure</title>
          <description>Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy.</description>
          <population>Transplanted participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maximum Grade 3-5 Toxicities</title>
        <description>The maximum grade of toxicities reported by participants over the study duration are tabulated. Per the CTCAE criteria, toxicities are graded on a scale of 0-5, with higher numbers indicating greater severity. The categories correspond as follows:
3 - severe; 4 - life-threatening; 5 - fatal</description>
        <time_frame>18 months</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maximum Grade 3-5 Toxicities</title>
          <description>The maximum grade of toxicities reported by participants over the study duration are tabulated. Per the CTCAE criteria, toxicities are graded on a scale of 0-5, with higher numbers indicating greater severity. The categories correspond as follows:
3 - severe; 4 - life-threatening; 5 - fatal</description>
          <population>Transplanted participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0-2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection Type</title>
        <description>The number and types of infection events reported are tabulated.</description>
        <time_frame>18 months post-transplant</time_frame>
        <population>Infection events</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Type</title>
          <description>The number and types of infection events reported are tabulated.</description>
          <population>Infection events</population>
          <units>Infection events</units>
          <param>Count of Units</param>
          <units_analyzed>Infection events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infection events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bacterial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Viral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fungal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Protozoal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infections</title>
        <description>The maximum severity of infections reported by participants are tabulated.
The number of infections and the number of patients experiencing infections will be tabulated by type of infection, severity, and time period after transplant. The cumulative incidence of severe, life-threatening, or fatal infections will be compared between the two treatment arms at 6, 12, and 18 months from transplant or until death.</description>
        <time_frame>18 months post-transplant</time_frame>
        <population>Transplanted participants</population>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infections</title>
          <description>The maximum severity of infections reported by participants are tabulated.
The number of infections and the number of patients experiencing infections will be tabulated by type of infection, severity, and time period after transplant. The cumulative incidence of severe, life-threatening, or fatal infections will be compared between the two treatment arms at 6, 12, and 18 months from transplant or until death.</description>
          <population>Transplanted participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Life Threatening or Fatal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cause of Death</title>
        <description>Primary cause of death was adjudicated using previously described criteria (Copelan et al. 2007). When relapse occurred, it was considered the primary cause of death regardless of other events.</description>
        <time_frame>18 months post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myeloablative Conditioning Regimen (MAC)</title>
            <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Reduced Intensity Conditioning (RIC)</title>
            <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cause of Death</title>
          <description>Primary cause of death was adjudicated using previously described criteria (Copelan et al. 2007). When relapse occurred, it was considered the primary cause of death regardless of other events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Relapse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Organ failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sudden death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Still alive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months post-randomization</time_frame>
      <desc>Serious Adverse Events (AE) are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected grade 3-5 AEs were required to be reported through the AE system per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Myeloablative Conditioning Regimen (MAC)</title>
          <description>One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
Busulfan and Fludarabine: (Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)
Busulfan and Cyclophosphamide: (Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Cyclophosphamide and Total Body Irradiation: (Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)</description>
        </group>
        <group group_id="E2">
          <title>Reduced Intensity Conditioning (RIC)</title>
          <description>One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
Fludarabine and Busulfan: (Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4
Fludarabine and Melphalan: (Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Venoocclusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Large granular lymphocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The Emmes Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

